Hematology Frontier

Multiple myeloma (MM) has long been a focus of hematology research due to its complex nature and the challenges it presents in treatment. As treatment methods continue to advance and new drugs emerge, patient survival rates and quality of life are receiving unprecedented attention. In this context, the accurate measurement of patient-reported outcomes (PROs) becomes increasingly important. It not only helps us gain a deeper understanding of patients’ real experiences but also provides guidance for developing more precise treatment strategies. At the 29th Annual Congress of the European Hematology Association (EHA 2024), held from June 13-16, Dr. Edward Laane from Tartu University in Estonia presented groundbreaking research that not only made significant strides in MM treatment but also offered new perspectives and methods for the standardization of PRO measurements. Hematology Frontier invited Dr. Edward Laane to share his team’s research findings and his special insights from the conference.

The "News Express" column aims to bridge the gap between cutting-edge research and clinical practice, enabling hematology enthusiasts and professionals to quickly grasp industry trends, spark innovative thinking, and broaden their professional horizons. Hematology News carefully curates the latest hematological research findings from top global journals. Each selected article represents a fusion of science and clinical practice, delivering the essence of hematology's advancements straight to you. Let knowledge transcend boundaries, and exploration never cease. We invite you to follow the column and join global hematology elites on a journey of scientific discovery! This issue features a case report from Haematologica on VHL-associated congenital polycythemia (CP).

Intravascular large B-cell lymphoma (IVLBCL) is a rare form of non-Hodgkin lymphoma with atypical clinical presentations, leading to high rates of misdiagnosis and missed diagnosis in clinical practice. There is an urgent need to improve the current status of diagnosis and treatment. Recently, the "2024 Northern Hematology and Oncology Immunotherapy Conference," hosted by the Tianjin Society of Hematology and Regenerative Medicine, was held grandly in the northern coastal city of Tianjin. The conference brought together renowned hematology experts from across the country, focusing on the immunotherapy of hematologic malignancies. They explored the latest advances in the diagnosis and treatment of various hematologic sub-specialties, the pathogenesis of hematologic tumors, and progress in immunotherapy. At the conference, Dr. Bing Xu from The First Affiliated Hospital of Xiamen University delivered an outstanding report titled "Advances in the Diagnosis and Treatment of Intravascular Large B-Cell Lymphoma—Interpretation of the 2023 Chinese Expert Consensus," providing crucial guidance for comprehensively understanding and recognizing this disease. Hematology Frontier invited Dr. Bing Xu to share further insights on this topic.

While radiotherapy is the recommended first-line treatment for mucosa-associated lymphoid tissue (MALT) lymphoma, for certain non-gastric MALT lymphomas in specific locations, radiotherapy may result in significant side effects that can affect patients' quality of life. Recently, the "2024 Northern Hematology and Oncology Immunotherapy Conference," hosted by the Tianjin Society of Hematology and Regenerative Medicine, was held grandly in the northern coastal city of Tianjin. The conference brought together renowned hematology experts from across the country, focusing on the immunotherapy of hematologic malignancies. They explored the latest advances in the diagnosis and treatment of various hematologic sub-specialties, the pathogenesis of hematologic tumors, and progress in immunotherapy. At the conference, Dr. Jun Shi from Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, delivered an insightful presentation titled "Treatment Options for Localized Non-Gastric MALT Lymphoma," offering valuable guidance for optimizing the treatment of this disease. Hematology Frontier invited Dr. Jun Shi to further discuss this topic.

On July 20, 2024, the 5th Lymphoma & Myeloma Immunotherapy and Targeted Therapy Conference, part of the Gaobo Medical Academic Conference, was successfully held in Beijing. With the core themes of "Precision, Integration, and Innovation," the conference closely followed the latest developments and cutting-edge topics from the 29th Annual Congress of the European Hematology Association (EHA 2024) and the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. During the event, Dr. Kai Fu from Roswell Park Comprehensive Cancer Center delivered an insightful presentation on "Progress Reports From the Northern American MCL Consortium." In an exclusive interview with Hematology Frontier, Professor Fu discussed the research progress of the North American Mantle Cell Lymphoma Program (NAMCLP) and the significance of a novel prognostic model for mantle cell lymphoma (MCL). The following is a summary of the interview.

In the vast river of life, blood flows like an unceasing stream, nourishing every inch of land and supporting the vitality and vigor of every life. Anemia, a seemingly inconspicuous…

In today’s information overload era, how can one stay updated on the latest advancements in the field? Here, we curate the most recent literature each month, focusing on hot topics and offering a comprehensive analysis of the latest developments in hematologic diseases. Join us as we track the latest trends, gain insights into scientific research, and explore the limitless possibilities in the world of hematology. Stay tuned—don’t miss our monthly updates!

Marginal zone lymphoma (MZL), a group of indolent mature B-cell lymphomas, presents a significant challenge in treatment selection due to its high heterogeneity. Despite improvements in survival rates for MZL patients with the advent of new drugs and advancements in clinical diagnostic and therapeutic techniques, developing a balanced management plan that addresses both efficacy and safety across a long disease course and lifetime management remains an urgent issue. At the recent "8th Academic Conference on Hematologic Oncology" organized by the Chinese Society of Clinical Oncology (CSCO), Dr. Huilai Zhang from Tianjin Medical University Cancer Institute & Hospital delivered a compelling presentation titled "Current Status and Treatment Progress for Chinese Patients with Marginal Zone Lymphoma." This report offers valuable insights and forward-looking guidance for comprehensively understanding the current state of MZL diagnosis and treatment in China and mastering the latest developments in the field. This article summarizes the key points of Professor Zhang's presentation for our readers.

To further enhance the diagnostic and treatment techniques for leukemia and lymphoma in China, the 8th Hematology Oncology Academic Conference was held from July 26 to 28 in Harbin. This event was jointly organized by the Chinese Society of Clinical Oncology (CSCO), the CSCO Leukemia Expert Committee, and the Lymphoma Expert Committee, and co-hosted by the Harbin Institute of Hematology and Oncology and Peking University Cancer Hospital. The conference aimed to provide a significant platform for in-depth learning and extensive exchange among experts and scholars in the field of hematologic oncology. On this occasion, Hematology Frontier had the privilege of inviting Dr. Qian Jiang from Peking University People's Hospital to share her insights on the treatment models and unmet needs for newly diagnosed chronic myeloid leukemia (CML) patients.

Hemophilia, a rare congenital bleeding disorder, is caused by pathogenic variants in the encoding genes, leading to the complete or partial deficiency of clotting factors VIII (Hemophilia A) or IX (Hemophilia B). Treating hemophilia involves certain complexities, and until now, no evidence-based clinical practice guidelines based on the GRADE methodology have been established to guide treatment. The International Society on Thrombosis and Haemostasis (ISTH) has developed evidence-based clinical practice guidelines aimed at systematically reviewing the relevant evidence to provide a scientific basis for treatment decisions in Hemophilia A and B, thereby supporting healthcare providers in their clinical practice. To this end, ISTH formed a globally representative, multidisciplinary guideline panel that prioritized clinical questions based on their urgency and the importance of outcomes to patients and clinicians.